Drugs / TQB3205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07482592 | Apr 2026 → Dec 2027 expected | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07482592 ↗ |
| Route | Oral | “TQB3205 capsule is taken orally once a day on an empty stomach” NCT07482592 ↗ |